These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 30943501)

  • 1. A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.
    Cheng M; Song Z; Qi Y; Wang X; Zhang L; Shi J; Wang M
    Oncol Res Treat; 2019; 42(5):269-274. PubMed ID: 30943501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052).
    Li R; Tian F; Qi Y; Ma L; Zhou T; Li Y; Hui T; Zhang L; Wang S; Song Z
    Sci Rep; 2019 Dec; 9(1):18135. PubMed ID: 31792258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
    Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
    Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
    Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
    Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
    Fracasso PM; Rodriguez LC; Herzog TJ; Fears CL; Goodner SA; Govindan R; Picus J; Rader JS; Tan BR; Arquette MA
    Cancer; 2003 Aug; 98(3):610-7. PubMed ID: 12879480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
    Chang AE; Wu QV; Jenkins IC; Specht JM; Gadi VK; Gralow JR; Salazar LG; Kurland BF; Linden HM
    Clin Breast Cancer; 2018 Feb; 18(1):e143-e149. PubMed ID: 29174203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
    Wesolowski R; Peereboom D; Weiss P; Elson P; Thomas Budd G
    Invest New Drugs; 2010 Aug; 28(4):502-8. PubMed ID: 19434371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
    Antolín S; Mel R; Ramos M; García-Palomo A; Almanza C; de Paz L; Calvo L; Alvarez E; González A; García-Mata J
    Clin Transl Oncol; 2011 Sep; 13(9):686-91. PubMed ID: 21865141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
    Saeki T; Takashima S; Ogita M; Tabei T; Adachi I; Tamura K; Takatsuka Y; Kanda K
    Breast Cancer; 2006; 13(2):159-65. PubMed ID: 16755111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.
    Malhotra V; Dorr VJ; Lyss AP; Anderson CM; Westgate S; Reynolds M; Barrett B; Perry MC
    Clin Breast Cancer; 2004 Dec; 5(5):377-84. PubMed ID: 15585077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer.
    Dellapasqua S; Mazza M; Rosa D; Ghisini R; Scarano E; Torrisi R; Maisonneuve P; Viale G; Cassano E; Veronesi P; Luini A; Goldhirsch A; Colleoni M
    Breast; 2011 Aug; 20(4):319-23. PubMed ID: 21397505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
    Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
    Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
    Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
    Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma.
    Wen XZ; Pan QZ; Xu BS; Xiao W; Weng DS; Zhao JJ; Xu HR; Huang Z; Niu XH; Zhang X
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):209-215. PubMed ID: 35022817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study.
    Tseng LM; Chen FM; Chen ST; Cheng FT; Chao TY; Dai MS; Kao WY; Yeh MH; Chen DR; Liu LC; Wang HC; Chang HT; Wang BW; Yu JC; Chen SC; Liao GS; Hou MF
    Oncol Res Treat; 2024; 47(10):484-495. PubMed ID: 39033747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.